RecruitingPhase 1NCT07239947

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and AD Patient

Sponsor

Bambusa Therapeutics

Enrollment

63 participants

Start Date

Aug 9, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BBT001 and a drug called Placebo for people with atopic dermatitis. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBBT001

BBT001 will be administered

DRUGPlacebo

Placebo will be administered

Locations(10)

The Second Hospital of Anhui Medical Univesity

Hefei, Anhui, China

The Second Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, China

Peking University People's Hospital

Beijing, Beijing Municipality, China

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

Wuxi Second People's Hospital

Wuxi, Jiangsu, China

Jiangsu University Affiliated Hospital

Zhenjiang, Jiangsu, China

Jiangxi Provincial Dermatology Hospital

Nanchang, Jiangxi, China

Shandong Provincial Hospital for Skin Diseases

Jinan, Shandong, China

Shanghai Dermatology Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07239947

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT006058781 location

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT0639791116 locations

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT065994111 location

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT076458204 locations